2023-08-03 02:23:12
SK Biopharmaceuticals announced on the 3rd that it launched the Scientific Advisory Board (SAB) to realize its mid- to long-term strategy and vision (Financial Story).
The committee is an organization under the direct control of the president and consists of five members, including world-renowned doctors, scientists, and experts in clinical, diagnosis, treatment, and new drug development.
File photo (Photo courtesy of SK Biopharmaceuticals)
Dr. Bang Bang-joo, who is considered a world-renowned authority in the field of gastric cancer-targeted anti-cancer and immuno-on-cancer clinical medicine, was appointed as the chairperson.
As an expert in anticancer and clinical development, Chairman Bang has made outstanding achievements in the clinical field for the past 30 years. Chairman of the Korean Cancer Society, Chairman of the Korean Society for Anticancer Therapy, Chairman of the Korean Society of Oncology, Professor of Internal Medicine at Seoul National University Hospital and Director of the Biomedical Research Institute, Clinical Trials He served as the center’s director.
Additionally, Jacqueline A. French, MD, Chief Medical and Innovation Officer, Epilepsy Foundation and Specialist in Epilepsy and Neurology, and Steve S. Chung, MD, Professor of Neurology, State University of New York School of Medicine, Specialist in Epilepsy Treatment and Neurology; ) Professor of Neurology, Banner University School of Medicine, Il Minn, Ph.D., specialist in radiopharmaceutical development and theranostics (companion diagnostic treatment) Professor Cheol-Young Maeng, professor of radiology and radiology, Johns Hopkins School of Medicine, and expert in drug development and pharmaceutical industry Doctors participate as advisory committee members.
Professor Jacqueline French has expertise in epilepsy and neurology, having served as president of the American Epilepsy Society (AES) and as a principal investigator on several clinical trials of new epilepsy drugs over the past 20 years.
Professor Steve Chung served as the 2020-2022 Chair of the American Academy of Neurology (AAN) Epilepsy Section and currently serves as the Chair of the American Academy of Epilepsy (AES) Corporate Advisory Board.
Professor Min Il is an expert in cancer diagnosis using molecular imaging and nanotechnology, RPT, and molecular genetic therapy development.
Dr. Maeng Cheol-young has been in charge of research and development in the pharmaceutical industry for 23 years, and in 2021 served as the head of SK Biopharm’s new drug development division.
In the future, experts in the field of CGT will be additionally recruited into the committee.
“It is an honor to serve as the first chairman of the SK Biopharmaceuticals Science Advisory Committee,” said Bang Bang-joo, chairman of the Science Advisory Committee. .
Lee Dong-hun, CEO of SK Biopharmaceuticals Corporation, said, “The top-notch scientific insights of the Science Advisory Committee, including Chairman Bang Young-joo, will be a clear compass in an uncertain future.” I hope this will be the case,” he said.
Meanwhile, SK Biopharmaceuticals operates a board of directors composed of external key experts and has established an advanced governance structure. The board of directors supports SK Biopharmaceuticals’ new business opportunities and new market creation, as well as prompt decision-making for global R&D projects.
In addition to Ahn Hae-young, CEO of Ahn Bio Consulting Inc., which is active in the US pharmaceutical industry, and Kim Min-ji, CEO of Cross Border Partners, SK Biopharmaceuticals appointed Song Min-seop, a professor at the Department of Business Administration at Sogang University, as outside directors to enhance global new drug investment capabilities and Expanded management capabilities.
1691040210
#Biopharmaceuticals #launched #advisory #committee #centered #Chairman #Bangjoo #Bang